Ludwig Institute for Cancer Research Limited

Ludwig Institute

Thomas Wolfel

Thierry R Boon-Falleur

Aline Van Pel

Vincent Brichard

Etienne De Plaen

Pierre G Coulie

Catia Traversari

Bernard Lethe

Jean-Christophe Renauld

Etienne DePlaen

Jean-Christope Renauld

Pierre Van Der Bruggen

Volker Lennerz

Martina Fatho

Serena Debo

Emmanuelle Wesarg

Silke Lubcke

Catherine Wolfel

Dirk Schadendorf

The invention relates to nucleic acid molecules coding for a tumor rejection antigen precursor. Specifically, the tumor rejection antigen precursor, or `TRAP', is processed into at least one tumor rejection antigen, which is presented by HLA-A2 molecules. Ramifications of the discovery are also set forth.

Precursor processed to at least one tumor rejection antigen presented by

The invention relates to nucleic acid molecules coding for a tumor rejection antigen precursor. Specifically, the tumor rejection antigen precursor, or 'TRAP', is processed into at least one tumor rejection antigen, which is presented by HLA-A2 molecules. Ramifications of the discovery are also set forth.

Isolated nucleic acid sequence coding for a tumor rejection antigen

Tumor rejection antigen precursor processed to at least one tumor

The invention relates to the identification of complexes of human leukocyte antigen molecules and tyrosinase derived peptides on the surfaces of abnormal cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention.

Isolated tyrosinase derived peptides and uses thereof

Isolated, tyrosinase derived peptides and uses thereof

Methods for determining disorders by assaying for a non-tyrosinase,

The invention relates to the identification of complexes of HLA-A2 and tyrosinase derived peptides on the surfaces of abnormal cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention.

Method for identifying individuals suffering from a cellular abnormality

The invention relates to the identification of complexes of human leukocyte antigen A2 (HLA-A2) molecules and a tyrosinase-derived peptide having the amino acid sequence Met Leu Leu Ala Val Leu Tyr Cys Leu Leu. The invention further relates to the detection of these complexes on the surface of abnormal cells and, in particular, on the surface of melanoma cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention.

Method for detecting complexes containing human leukocyte antigen A2

Growing community of inventors

Mainz, Germany

Thomas Wolfel